Cary Gross, professor of medicine and of epidemiology at Yale School of Medicine, has been working with a dataset of 35,000 non-small cell lung cancer patients, looking for signs of disparities in access to PD-1 checkpoint inhibitors.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
